BOHEMIA, NY / ACCESSWIRE / April 16, 2024 / Scientific Industries, Inc. (OTCQB:SCND) (“SI”) announced the appointment of Michael Blechman to the Board of Directors of SI effective April 12, 2024. Mr. Blechman filled a Board vacancy and replaces Mr. Marcus Frampton, who recently resigned, as a Class B director.
John A. Moore, Chairman of SI, said “After knowing Mr. Blechman for the past four years and watching his success in building a leading bioprocessing controls business and ultimately selling it, Ms. Santos, our CEO, and I felt he would add outstanding commercial insights to assist SI with the commercial launch of the DOTS multiparameter sensor platform. Mr. Blechman has already made introductions to important members of the biotech community. He is a Board member who will roll up his sleeves and help us grow the business.”
Mr. Blechman commented: “I’m honored to join the SI Board and looking forward to offering my skills and operational experience to augment my fellow board members’ own expertise and skills. Scientific Industries appears to be at the cusp of great things and I’m excited to be a part of the process.”
Michael Blechman brings over three decades of experience in sales, marketing, operations and strategic planning. As CEO of Automated Control Concepts, Inc. (“ACC”) he led the organization through 20 years of profitable operations and positive shareholder returns, culminating in a successful transaction with a private equity investor. While at ACC, Michael spearheaded their entry into the biotech product space with the introduction of the highly effective Lab Owl bioreactor control and information system.
About Scientific Industries, Inc.
Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product platform DOTS. Scientific Industries’ products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.
About Scientific Bioprocessing, Inc. (“SBI”)
SBI offers solutions for digitally simplified bioprocessing in the life science industry. SBI’s DOTS Platform turns the standard shake flask into a smart mini bioreactor by providing modern bioprocessing sensors (for e.g., continuous monitoring of biomass, dissolved oxygen, and fluorescence) and control options (as e.g., automated, parameter-based feeding) along with an innovative software for easy sensor control and data monitoring. SBI is committed to delivering exceptional customer service and is a subsidiary of Scientific Industries Inc. To learn more, visit www.scientificbio.com.
“Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company’s Securities and Exchange Commission reports, including our annual report on Form 10-K.”
Company Contact:
Helena R. Santos | or: | |
CEO and President | Joe Dorame | |
Phone: 631-567-4700 | Lytham Partners, LLC | |
hsantos@scientificindustries.com | Phone: 602-889-9700 | |
info@scientificindustries.com | SCND@lythampartners.com |
SOURCE: Scientific Industries, Inc.
View the original press release on accesswire.com
NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…
Diarrhea is one of the most common reasons for veterinary visits for dogs and the…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…